Cronos Group Subsidiary To Acquire All Outstanding Shares Of CanAdelaar For Up-Front Consideration Of $67M Plus Cash Earnout Of 0.5x Normalized EBITDA In 2026 And 2027

Cronos to acquire CanAdelaar for up-front cash consideration of US$67.0M1 plus cash earnout of 0.5x normalized EBITDA in 2026 and 2027

Up-front consideration represents approximately 1.4x CanAdelaar LTM revenue and 2.4x LTM EBITDA2

Will give Cronos #1 market share3 in the largest adult-use cannabis market in Europe

Enables borderless product strategy, leveraging investments in genetics, R&D, and product development

TORONTO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, is pleased to announce that its wholly-owned subsidiary has entered into a definitive share sale and purchase agreement (the "Purchase Agreement") to acquire all of the outstanding shares of CanAdelaar B.V. ("CanAdelaar"), the largest cannabis company3 operating within the Netherlands' adult-use cannabis pilot program (the "Wietexperiment"). Under the Purchase Agreement, the shares of CanAdelaar will be acquired for up-front consideration of €57.5 million, or US$67.0 million,1 subject to certain customary adjustments, with additional contingent consideration payable in cash based on 0.5x of CanAdelaar's normalized EBITDA in 2026 and 2027 (the "Transaction").